Latest news with #MedicalServices
Yahoo
09-07-2025
- Business
- Yahoo
GDRX vs. HQY: Which Stock Is the Better Value Option?
Investors with an interest in Medical Services stocks have likely encountered both GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits. Currently, GoodRx Holdings, Inc. has a Zacks Rank of #2 (Buy), while HealthEquity has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that GDRX has an improving earnings outlook. But this is just one factor that value investors are interested in. Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels. The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value. GDRX currently has a forward P/E ratio of 12.80, while HQY has a forward P/E of 27.57. We also note that GDRX has a PEG ratio of 1.15. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. HQY currently has a PEG ratio of 1.32. Another notable valuation metric for GDRX is its P/B ratio of 2.64. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, HQY has a P/B of 4.2. These metrics, and several others, help GDRX earn a Value grade of B, while HQY has been given a Value grade of D. GDRX stands above HQY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that GDRX is the superior value option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
03-07-2025
- Business
- Yahoo
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering CVS Health (CVS), which belongs to the Zacks Medical Services industry. When looking at the last two reports, this drugstore chain and pharmacy benefits manager has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 32.64%, on average, in the last two quarters. For the last reported quarter, CVS Health came out with earnings of $2.25 per share versus the Zacks Consensus Estimate of $1.71 per share, representing a surprise of 31.58%. For the previous quarter, the company was expected to post earnings of $0.89 per share and it actually produced earnings of $1.19 per share, delivering a surprise of 33.71%. Thanks in part to this history, there has been a favorable change in earnings estimates for CVS Health lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. CVS Health has an Earnings ESP of +6.35% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #2 (Buy), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on July 31, 2025. With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss. Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate. Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-06-2025
- Business
- Yahoo
OGN or DOCS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits. Organon and Doximity are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. This means that OGN's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one piece of the puzzle for value investors. Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels. The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value. OGN currently has a forward P/E ratio of 2.83, while DOCS has a forward P/E of 48.14. We also note that OGN has a PEG ratio of 1.08. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. DOCS currently has a PEG ratio of 5.22. Another notable valuation metric for OGN is its P/B ratio of 4.82. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, DOCS has a P/B of 9.76. Based on these metrics and many more, OGN holds a Value grade of A, while DOCS has a Value grade of D. OGN is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that OGN is likely the superior value option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Organon & Co. (OGN) : Free Stock Analysis Report Grupo Aeroportuario Del Pacifico, S.A. de C.V. (PAC) : Free Stock Analysis Report American Water Works Company, Inc. (AWK) : Free Stock Analysis Report Ladder Capital Corp (LADR) : Free Stock Analysis Report Chewy (CHWY) : Free Stock Analysis Report Adyen N.V. Unsponsored ADR (ADYEY) : Free Stock Analysis Report Doximity, Inc. (DOCS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
17-06-2025
- Business
- Yahoo
Are Options Traders Betting on a Big Move in BrightSpring Stock?
Investors in BrightSpring Health Services, Inc. BTSG need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $12.50Call had some of the highest implied volatility of all equity options today. Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. Clearly, options traders are pricing in a big move for BrightSpring shares, but what is the fundamental picture for the company? Currently, BrightSpring is a Zacks Rank #2 (Buy) in the Medical Services industry that ranks in the Top 27% of our Zacks Industry Rank. Over the last 60 days, four analysts have increased their earnings estimates for the current quarter, while none dropped the estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from 17 cents per share to 21 cents in that period. Given the way analysts feel about BrightSpring right now, this huge implied volatility could mean there's a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk. Click to see the trades now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BrightSpring Health Services, Inc. (BTSG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
13-06-2025
- Health
- Zawya
Principal Secretary (PS) Oluga Chairs Meeting on Urology Centre Project
The Principal Secretary for Medical Services Dr. Ouma Oluga on Friday June 13, 2025 chaired a consultative meeting with the African Development Bank and the National Treasury to review progress on the implementation of the East Africa Centre of Excellence in Urology and Nephrology project. The meeting brought together key stakeholders, including Ms. Nadege Balima from the African Development Bank, Mr. Samuel Nyoike from the National Treasury, and Dr. Ajuck Hossin from the Ministry of Health. Distributed by APO Group on behalf of Ministry of Health, Kenya.
